1. Fei-Yan-Qing-Hua decoction decreases hyperinflammation by inhibiting HMGB1/RAGE signaling and promotes bacterial phagocytosis in the treatment of sepsis.
- Author
-
Zhang, Huan, Xu, Guihua, Wu, Xiao, Xu, Yanwu, Xu, Lirong, Zou, Yingxiang, Yang, Xiaodong, Pan, Lingyun, Lei, Biao, Mu, Jingwen, Huang, Qilin, Ma, Yuhe, Duan, Naifan, Zhang, Wei, and Zheng, Yuejuan
- Subjects
- *
INFLAMMATION prevention , *LIPOPOLYSACCHARIDES , *BIOLOGICAL models , *CYTOKINES , *KLEBSIELLA , *HERBAL medicine , *PHAGOCYTOSIS , *CATHELICIDINS , *INJECTIONS , *STAINS & staining (Microscopy) , *ANIMAL experimentation , *WESTERN immunoblotting , *CARBAPENEM-resistant bacteria , *INTRAPERITONEAL injections , *SEPSIS , *KLEBSIELLA infections , *CELLULAR signal transduction , *ENZYME-linked immunosorbent assay , *FLUORESCENT antibody technique , *POLYMERASE chain reaction , *CHINESE medicine , *MICE - Abstract
Fei-Yan-Qing-Hua decoction (FYQHD), derived from the renowned formula Ma Xing Shi Gan tang documented in Zhang Zhong Jing's "Treatise on Exogenous Febrile Disease" during the Han Dynasty, has demonstrated notable efficacy in the clinical treatment of pneumonia resulting from bacterial infection. However, its molecular mechanisms underlying the therapeutic effects remains elusive. This study aimed to investigate the protective effects of FYQHD against lipopolysaccharide (LPS) and carbapenem-resistant Klebsiella pneumoniae (CRKP)-induced sepsis in mice and to elucidate its specific mechanism of action. Sepsis models were established in mice through intraperitoneal injection of LPS or CRKP. FYQHD was administered via gavage at low and high doses. Serum cytokines, bacterial load, and pathological damage were assessed using enzyme-linked immunosorbent assay (ELISA), minimal inhibitory concentration (MIC) detection, and hematoxylin and eosin staining (H&E), respectively. In vitro , the immunoregulatory effects of FYQHD on macrophages were investigated through ELISA, MIC, quantitative real-time PCR (Q-PCR), immunofluorescence, Western blot, and a network pharmacological approach. The application of FYQHD in the treatment of LPS or CRKP-induced septic mouse models revealed significant outcomes. FYQHD increased the survival rate of mice exposed to a lethal dose of LPS to 33.3%, prevented hypothermia (with a rise of 3.58 °C), reduced pro-inflammatory variables (including TNF-α, IL-6, and MCP-1), and mitigated tissue damage in LPS or CRKP-induced septic mice. Additionally, FYQHD decreased bacterial load in CRKP-infected mice. In vitro , FYQHD suppressed the expression of inflammatory cytokines in macrophages activated by LPS or HK-CRKP. Mechanistically, FYQHD inhibited the PI3K/AKT/mTOR/4E-BP1 signaling pathway, thereby suppressing the translational level of inflammatory cytokines. Furthermore, it reduced the expression of HMGB1/RAGE, a positive feedback loop in the inflammatory response. Moreover, FYQHD was found to enhance the phagocytic activity of macrophages by upregulating the expression of phagocytic receptors such as CD169 and SR-A1. FYQHD provides protection against bacterial sepsis by concurrently inhibiting the inflammatory response and augmenting the phagocytic ability of immune cells. [Display omitted] • FYQHD protected against Gram-negative bacteria, including CRKP-induced sepsis. • FYQHD inhibited the translation of inflammatory cytokines by inhibiting the PI3K/AKT/mTOR/4E-BP1 pathway. • FYQHD inhibited the amplification of the inflammatory response by HMGB1/RAGE signaling pathway. • FYQHD promoted the phagocytosis by promoting the expression of CD169 and SR-A1. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF